Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607640 | 0.90 | LMNA (0.59) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL7275713 | 0.83 | GLA (0.69) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL11191041 | 0.83 | ALOX15 (0.56) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL2419143 | 0.83 | TSHR (0.59) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL14930159 | 0.83 | LMNA (0.59) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL9527006 | 0.81 | ALOX15 (0.54) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL11191103 | 0.81 | ALOX15 (0.54) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL9643771 | 0.80 | TSHR (0.65) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL5203267 | 0.80 | ALOX15 (0.53) | LMNATSHRPOLBALDH1A1RAB9A | |
| SCHEMBL12496081 | 0.80 | ALOX15 (0.53) | LMNATSHRPOLBALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9090538-B2 | Uses of esteramide compounds | RHODIA OPERATIONS (FR) | 2015-07-28 | — | — | US | disclosed |
| US-9056817-B2 | Arylated β-dicarbonyl compounds and process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-06-16 | — | — | US | disclosed |
| US-9056817-B2 | Arylated β-dicarbonyl compounds and process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-06-16 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140228592-A1 | ARYLATED BETA-DICARBONYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-14 | — | — | US | disclosed |
| EP-2637669-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130210933-A1 | NOVEL USES OF ESTERAMIDE COMPOUNDS | RHODIA OPERATIONS (FR) | 2013-08-15 | — | — | US | disclosed |
| US-20120189492-A1 | FULLERENE COMPOSITIONS AND METHODS FOR PHOTOCHEMICAL PURIFICATION | WILLIAM MARSH RICE UNIVERSITY (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-4407797-A | ANTIULCER AGENT | RHONE-POULENC SANTE (FR) | 1983-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210933-A1 | NOVEL USES OF ESTERAMIDE COMPOUNDS | CECR2, CES2, ERLIN2 | LMNA 1804/4885TSHR 885/4885POLB 3045/4885 |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | LMNA 1475/4885TSHR 4224/4885POLB 1743/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | LMNA 1475/4885TSHR 4224/4885POLB 1743/4885 |
| US-20140228592-A1 | ARYLATED BETA-DICARBONYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | CYP51A1, DDT, CYP3A4 | LMNA 2589/4885TSHR 4210/4885POLB 1487/4885 |
| US-20120189492-A1 | FULLERENE COMPOSITIONS AND METHODS FOR PHOTOCHEMICAL PURIFICATION | DNMT1, ALKBH2, ALKBH1 | LMNA 2799/4885TSHR 3164/4885POLB 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.